• S&P 500: 1,342.64
  • Change: -0.69%
$8.50 -0.70 (-7.61%)
2/10/2012 3:52 PM

Gentium S.p.A. (ADR) (NASDAQ:GENT)

CAPS Rating: 2 out of 5

A biopharmaceutical company engaged in the research, development and manufacture of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments.

Current Price $8.50 Mkt Cap $127.21M
Open $9.04 P/E Ratio 15.20
Prev. Close $9.20 Div. (Yield) N/A (N/A)
Daily Range $8.25 - $9.04 Volume 37,555
52-Wk Range $5.31 - $13.69 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think GENT will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

26 Outperform
10 Underperform
 

All-Star Players

10 Outperform
2 Underperform
 

Wall Street

3 Outperform
0 Underperform
 

Top GENT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

OklaBoston (< 20)
Submitted June 17, 2010

Tiny biotech company broke into the black on free cash flow in most recent quarter. Expensive on most price measures but that's to be expected at this point in the company's development isn't it?

Add Comment | Reply | Report this Post

zzlangerhans (99.30)
Submitted January 20, 2012

Zoicks! How did I miss that late rush on Genta on Wednesday? Really, I can't take my eyes off some of these stocks for a minute before they're reaching into the cookie jar.I'm pretty confident that there's no new reason to be optimistic about Genta.… More

2 Comments | Reply | Report this Post
GENT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about GENT.

Recs

1
Member Avatar zzlangerhans (99.30) Submitted: 1/20/2012 12:32:46 PM : Underperform Start Price: $7.24 GENT Score: -14.97

Zoicks! How did I miss that late rush on Genta on Wednesday? Really, I can't take my eyes off some of these stocks for a minute before they're reaching into the cookie jar.

I'm pretty confident that there's no new reason to be optimistic about Genta. Defibrotide sales under the named patient programs seem to have topped out around 5M Euros quarterly. As noted previously, the company withdrew the defibrotide NDA in August after getting a heads up that the FDA would refuse to file. The only significant new development is that the company received the CHMP day 120 list of questions. In October they issued a press release stating they would respond to the questions by the end of 2011. At the end of 2011, they issued a new press release that they would respond to the questions in Q1 2012. Why didn't I ever use that tactic with my chemistry teacher?

I don't think defibrotide will ever be approved in the US or Europe. The data simply doesn't support it, although after three years many people seem to have forgotten the results of the trials. Meanwhile, the company's end run around the regulatory bodies through named patient programs is likely unsustainable.

Report this Post 2 Comments | Reply | Permalink

Recs

0
Member Avatar jrusso9722 (< 20) Submitted: 10/7/2010 3:28:22 PM : Outperform Start Price: $7.00 GENT Score: +5.47

GENT solves serious medical problems, for which there is no cure. Other clinical trials on horrible diseases keep evolving. Long Gent

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar LorenCobb (45.45) Submitted: 6/19/2010 2:34:38 AM : Outperform Start Price: $5.10 GENT Score: +48.03

Tailored single-strand DNA and RNA aptamers!

Report this Post Add Comment | Reply | Permalink
View All 5 Pitches »

Leaderboard

Find the members with the highest scoring picks in GENT.

Score Leader

ValueRider

ValueRider (99.62) Score: +86.66

The Score Leader is the player with the highest score across all their picks in GENT.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
thisyearswinners 48.31 7/7/2010 Outperform 5Y $4.20 +102.38% +28.32% +74.06 0 Comment
lost402 42.00 6/14/2010 Outperform 3M $4.50 +88.89% +21.43% +67.46 0 Comment
lassinator 60.99 6/14/2010 Outperform NS $4.50 +88.89% +21.43% +67.46 0 Comment
stockerace 96.95 3/27/2007 Underperform 3M $19.43 -56.25% -0.61% +55.64 0 Comment
OverAnalyze 61.59 3/26/2007 Underperform 3W $19.15 -55.61% -1.13% +54.48 0 Comment
cnikigreene 60.23 4/30/2007 Underperform 3W $18.99 -55.24% -5.19% +50.05 1 Comment
LorenCobb 45.45 6/21/2010 Outperform 5Y $5.10 +66.67% +18.64% +48.03 1 Comment
Z200 60.20 1/17/2012 Outperform 3W $5.80 +46.55% +3.17% +43.38 0 Comment
NOSMATTHEW 89.96 8/18/2011 Outperform 3W $6.16 +37.99% +17.02% +20.97 0 Comment
emeraldvale < 20 9/2/2011 Outperform 5Y $6.55 +29.77% +13.33% +16.45 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackWedbush 84.91 3/15/2011 Outperform NS $9.00 -5.56% +6.01% -11.57 0 Comment
TrackBroadpointAmTech 90.30 9/21/2007 Outperform NS $23.50 -63.83% -7.93% -55.90 0 Comment
TrackOppenheimer 79.23 8/21/2007 Outperform NS $18.75 -54.67% -2.31% -52.36 0 Comment

Featured Broker Partners